Clinical Trial: A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

U.S., Oct. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07222332) titled 'A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)' on Oct. 27.

Brief Summary: The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.

Study Start Date: March, 2026

Study Type: INTERVENTIONAL

Condition: Diabetes Mellitus, Type 1

Intervention: DRUG: Baricitinib

Administered orally

DRUG: Placebo

Administered orally

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Eli Lilly and Company

Disclaime...